ライフサイエンスコーパス: disease stage

1 amyotrophic lateral sclerosis from the early disease stage.

2 HCV, with efficacy dependent on genotype and disease stage.

3 tive, the sensitivity was 100% regardless of disease stage.

4 data on the immune status of this particular disease stage.

5 gs was observed in patients at a less severe disease stage.

6 lack of cancer-specific information such as disease stage.

7 obal Initiative for Chronic Obstructive Lung Disease stage.

8 ing in amyotrophic lateral sclerosis at late disease stage.

9 elaying treatment until the subsequent liver disease stage.

10 ) and QOL measures were inversely related to disease stage.

11 mice that received treatment at an advanced disease stage.

12 vel of FL produced >/=1 dB of DeltaMD at any disease stage.

13 t contribute to TB pathology at the advanced disease stage.

14 otrophic lateral sclerosis patients in early disease stage.

15 CD4(+) count, and World Health Organization disease stage.

16 optimal MDS-NK cell function irrespective of disease stage.

17 wing protein fragments that were specific to disease stage.

18 7 younger patients (<70 years) with the same disease stage.

19 CLL after adjusting for age, sex, race, and disease stage.

20 CLL after adjusting for age, sex, race, and disease stage.

21 ecific and overall survival included age and disease stage.

22 function of selected RNA targets at an early disease stage.

23 LRR after BCT is driven by tumor biology and disease stage.

24 was similar among all 4 quartiles except for disease stage.

25 ific NCCN guidelines was determined based on disease stage.

26 for these diseases, with therapy adjusted to disease stage.

27 leep quality resembling signs of a prodromal disease stage.

28 trophy progresses further during the chronic disease stage.

29 Oncology Group performance status, age, and disease stage.

30 depth, ulceration of the primary lesion, and disease stage.

31 stratified according to centre and clinical disease stage.

32 y although therapeutic benefit may depend on disease stage.

33 ses in intrinsic excitability that depend on disease stage.

34 s a high risk of distant metastasis at every disease stage.

35 in intermediate monocyte subsets in advanced disease stages.

36 istribution of HBV genotypes among different disease stages.

37 s and a myostatin inhibitor in mice at later disease stages.

38 es in a DTI metric that reflect distinct ALS disease stages.

39 survival of rods and cones at early and late disease stages.

40 nd uncovered additional heterogeneity within disease stages.

41 nts with multiple sclerosis (MS) at distinct disease stages.

42 We then treated mice at early, mid, or late disease stages.

43 dicating their greater usefulness in earlier disease stages.

44 driving cellular compartments at the various disease stages.

45 obal Initiative for Chronic Obstructive Lung Disease stages.

46 se include early, intermediate, and atrophic disease stages.

47 and retention of MPs play at these different disease stages.

48 med before MDS patients progress to advanced disease stages.

49 tages, whereas volume loss dominates in late disease stages.

50 lymphocytes of melanoma patients at advanced disease stages.

51 g gammadelta and CD4(+) T cells at different disease stages.

52 s from these patients were examined at later disease stages.

53 ith preserved ejection fraction at the early disease stages.

54 nts, with the highest levels at the advanced disease stages.

55 tic nerves with special focus on preclinical disease stages.

56 bunit were only observed at late Parkinson's disease stages.

57 on, likely representing in early Alzheimer's disease stages.

58 asure quality of life changes in the mildest disease stages.

59 rocess during preclinical and early clinical disease stages.

60 ic markers for early infection detection and disease stages.

61 ipheral inflammation occurs early at the MCI disease stages.

62 rsodeoxycholic acid, may be effective at all disease stages.

63 ents are dramatically less effective at late disease stages.

64 broader age spectrum and patients of various disease stages.

65 amyloid-beta species across brain areas and disease stages.

66 luence plasma drug concentrations in the two disease stages.

67 t treatment stratification at early and late disease stages.

68 in patients with parkinsonism, even at early disease stages.

69 eficial in detecting small tumor lesions and disease staging.

70 free of HF risk factors or structural heart disease (Stage 0), 52% were categorized as Stage A, 30%

71 obal Initiative for Chronic Obstructive Lung Disease stage 1, where each exacerbation was associated

72 A total of 72 patients had advanced-stage disease (stage 1B/2B/3 or 4) and received VEPEMB 6 times

73 Within each disease stage, 1q gain was associated with inferior EFS

74 obal Initiative for Chronic Obstructive Lung Disease stage 2 and 3 subjects.

75 tor therapy when they reached chronic kidney disease stage 2 or better.

76 obal Initiative for Chronic Obstructive Lung Disease stages 2 and higher chronic obstructive pulmonar

77 I, 4.28-79.4 for 3-4 quadrants vs no preplus disease), stage 2 ROP (OR, 4.13; 95% CI, 2.13-8.00 vs no

78 d diagnosis for certain categories (eg, plus disease, stage 2 disease or worse, and treatment-requiri

79 BW and prematurity, the presence of preplus disease, stage 2 ROP, retinal hemorrhage, and the need f

80 Measurements: Chronic kidney disease (stages 3 and 4) was defined as an estimated glo

81 oportion of HRS2 patients had chronic kidney disease stage 3 (CKD3) at 3 (53.8% vs 28.4%; P = 0.007)

82 onfidence interval [CI], 1.78-8.55), as were disease stage 3 at presentation (OR, 5.62; 95% CI, 1.59-

83 ients, whereas 3 patients had chronic kidney disease stage 3 or 4, and 1 patient (1.1%) still require

84 a in 20/46 (43%) patients and chronic kidney disease stage 3 or above in 42/49 (86%) patients.

85 etiapine had reduced rates of chronic kidney disease stage 3 or more severe, following adjustment for

86 Patients with chronic kidney disease stages 3 to 5 (glomerular filtration rate <60 mL

87 s are common in patients with chronic kidney disease stages 3 to 5 and are associated with a substant

88 uss resistant hypertension in chronic kidney disease stages 3-5 (ie, patients with an estimated glome

89 Diagnosis in the most advanced disease stage (3) occurred in 307 (47%) of 657 patients

90 in decade 1 demonstrated advanced stages of disease (stage 3B or worse) compared with 20% of eyes in

91 HCV genotype 1 infection and chronic kidney disease (stage 4-5 with or without haemodialysis depende

92 NuMA expression decreased in late disease stage 4 endometrioid EOCs.

93 ficant difference in rates of chronic kidney disease stage 4 or more severe, type 2 diabetes mellitus

94 bulo-interstitial disease, or chronic kidney disease stages 4-5 at baseline, and those who had underg

95 22 patients with chronic kidney disease stage 5 undergoing intermittent hemodialysis tre

96 en treating all patients regardless of their disease stage after 2016, was found to be cost-effective

97 mpact of major clinical variables, including disease stage, age of disease onset and accelerated brai

98 as hyperlipidemia, smoking, medication, and disease stage, all of which affect the thiol redox state

99 At later disease stages, also anterograde mitochondrial transport

100 In addition to disease stage, amyloid-beta pathology affects cerebral b

101 At different disease stages an adeno associated viral vector encoding

102 with anti-NMDAR encephalitis after the acute disease stage and 25 healthy control subjects underwent

103 se progression; however, the effect of liver disease stage and antiviral therapy on the risk of clini

104 These findings show that both disease stage and cell type must be considered when deve

105 ortical thickness can be useful in assessing disease stage and cognitive impairment in patients with

106 +) myeloid cells, IL30 levels increased with disease stage and correlated with recurrence.

107 Patients were stratified at randomisation by disease stage and ECOG performance status.

108 n technique, randomisation was stratified by disease stage and geographical region.

109 n technique, randomisation was stratified by disease stage and geographical region.

110 Mutations were associated with advanced disease stage and involvement of multiple lymphoid sites

111 t antileukemic activity across categories of disease stage and mutation status.

112 Knees were matched according to radiographic disease stage and patient sex and age.

113 were significantly associated with advanced disease stage and poor patient prognosis (P<0.01).

114 mpal atrophy rate is a reliable biomarker of disease stage and progression and could also be consider

115 erm (>/=2 years) symptoms, adjusted for Lyme disease stage and severity at diagnosis.

116 that tumor GRP78 expression correlates with disease stage and that anti-GRP78 AutoAb levels parallel

117 tatus of the heart may vary depending on the disease stage and that treatment should be initiated bef

118 ntified in MS and whether they are linked to disease stage and/or disability.

119 ious pathological conditions, correlate with disease stage and/or patient survival, has stimulated in

120 tinct bacterial populations in the different disease stages and also depending on the level of inflam

121 Inflammation is typically present in all disease stages and associated with the development of fi

122 accumulations distributed differently across disease stages and brain areas, while N-terminally trunc

123 tment of OPSCC are outlined for a variety of disease stages and clinical scenarios.

124 sed experimental platforms that recapitulate disease stages and clonal architecture.

125 ction of diffuse myocardial disease in early disease stages and complements late gadolinium enhanceme

126 HRR decreased in C2 compared with C1 for all disease stages and grades.

127 Immune defects occur already at early disease stages and impact the clinical course.

128 ecause epileptic activity can occur at early disease stages and might contribute to pathogenesis.

129 -20% in early disease stages to -61% in late disease stages and preceded fibrosis.

130 emor, and postural instability) are used for disease staging and assessment of progression.

131 tron emission tomography is a useful tool in disease staging and follow-up.

132 es require valid biomarkers for standardized disease staging and for evaluation of progression and th

133 able and a reliable prognostic algorithm for disease staging and for guiding management decisions is

134 that provides reproducible, highly accurate disease staging and monitoring of therapeutic effects.

135 ntial information for accurate evaluation of disease staging and progression, yet the poor cellular u

136 uch improvements could lead to more accurate disease staging and robust measurements of changes in ta

137 hat must be answered to enable sophisticated disease staging and the development of new strategies to

138 0% within 1 year of diagnosis (regardless of disease stage), and 20% per year thereafter, chronic pre

139 ined the effect of ageing, HIV infection (by disease stage), and their interaction on five neurocogni

140 obal Initiative for Chronic Obstructive Lung Disease stage, and COPD disease status.

141 subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superio

142 community diversity such as dominant taxon, disease stage, and gender.

143 ng abnormalities in SCA2 differ depending on disease stage, and interventions targeted towards correc

144 key clinical variables (e.g., tumor subtype, disease stage, and patient survival time) and other mole

145 stratified, in a block size of two, by age, disease stage, and performance status.

146 e (adenocarcinoma or neuroendocrine), phase, disease stage, and treatment approach is reported.

147 f radiation therapy included marital status, disease stage, and type of lymph node surgery.

148 in hypoxia tracer uptake, even in the early disease stages, and a 45-fold elevation in ROS expressio

149 t-specific differences in infectivity across disease stages, and on the epidemic level we considered

150 s critical for HIV prevention, screening and disease staging, and monitoring antiretroviral therapy (

151 Predictors of genital shedding were HIV disease stage, antiretroviral regimen, and genital ulcer

152 n levels and mitochondrial function as early disease stages are initiated.

153 and prognostic markers used in more advanced disease stages are not applicable) will lead to the iden

154 es and the implications for TB diagnosis and disease staging are poorly understood.

155 d variables such as age of disease onset and disease stage as well alterations of structural brain ma

156 a and full-length amyloid-beta, depending on disease stage as well as brain area, and determined how

157 y pathways was reduced in the lungs at later disease stages as were splenocyte IL12/23p40 and IFN-gam

158 y stratified by sex, CD4 cell count, and WHO disease stage at enrolment in care and initiation of ant

159 ine the association of insurance status with disease stage at presentation, treatment, and survival a

160 hnique was used to adjust for differences in disease stage at presentation.

161 ender, race, performance score, disease, and disease stage at transplantation.

162 Promisingly, NOD mice given transient late disease stage BAFFR-Fc monotherapy were rendered T1D res

163 y begin as an astrogliopathy at a very early disease stage but neuronal lesions gradually take over a

164 lantation (alloHSCT) outcomes by disease and disease stage can limit statistical power.

165 th Organization human immunodeficiency virus disease stage, CD4(+) T-cell counts, and previous histor

166 ponents were quantified, and were related to disease stage, clinical severity, and MECP2 mutation typ

167 Treatment decisions should also consider disease stage, comorbidities, and patient preferences.

168 ion and translocation, which correlated with disease stage, compared with healthy explants.

169 ted antiretroviral therapy (ART) at advanced disease stages, continue to have increased age-related m

170 rly inflammation, as well as mild and severe disease stages, could be distinguished.

171 This proliferation persisted into the late disease stage (day 56 post-immunization), indicating the

172 An obstacle in such an approach is that disease stage-defining biomarkers are still lacking.

173 Here, we determined disease stage-dependent changes in myocardial efficiency

174 f neurological disturbances independently of disease stage determined by current criteria.

175 llagen FSR in NAFLD increased with advancing disease stage (e.g., higher in NASH than nonalcoholic fa

176 stem cell (iPSC) lines capturing a range of disease stages encompassing preleukemia, low-risk MDS, h

177 A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and

178 (primary GBMs), providing no access to early disease stages for assessing disease progression events.

179 Our model includes both colonization and disease stages for patients and health care workers, as

180 ce costs were directly related to increasing disease stages from 0 to 4 (p<0.001).

181 sue samples that were collected at different disease stages from desmoglein 2-mutant mice, a well cha

182 status, residual disease after surgery, and disease stage further optimized outcome classification.

183 s showed that patients at an advanced severe disease stage had a higher frequency of terminally diffe

184 Because patients with different liver disease stages have been treated with great success incl

185 al, gastric, and pancreatic cancer; advanced disease stage; high Charlson comorbidity index score; an

186 age based on the following categories: liver disease stage, HIV co-infection, prescriber type, and dr

187 riteria for sofosbuvir with respect to liver disease staging, HIV co-infection, prescriber type, and

188 iation among kidney function (chronic kidney disease stage), HRQoL, and patient-reported side effects

189 ortality among participants with early-stage disease (stages I and II; HR, 1.61; 95% CI, 1.26 to 2.04

190 obal Initiative for Chronic Obstructive Lung Disease stage I COPD and 20 healthy subjects completed t

191 obal Initiative for Chronic Obstructive Lung Disease stage I to II) before and after treatment with f

192 s of 500 cells per muL or more, and with WHO disease stage I, had the highest life expectancies.

193 obal Initiative for Chronic Obstructive Lung Disease stage I-IV COPD, and smoking and never-smoking c

194 obal Initiative for Chronic Obstructive Lung Disease) stages I-IV: 9.4, 42.5, 37.5, and 10.5%, respec

195 y more patients in the surgery alone arm had disease stage IB/IIA (55.3% v 48.8%).

196 Localized disease (stage IE or IIE) was commonly treated with exte

197 obal Initiative for Chronic Obstructive Lung Disease stage II-IV) underwent hyperpolarized (129)Xe MR

198 obal Initiative for Chronic Obstructive Lung Disease stage II-IV.

199 6 PD patients who were divided into three PD disease stages (IIa, III, and IV) according to the Unifi

200 1; 95% CI, 1.26 to 2.04), but not late-stage disease (stages III and IV; HR, 1.05; 95% CI, 0.91 to 1.

201 obal Initiative for Chronic Obstructive Lung Disease stages III-IV, and one or more moderate COPD exa

202 gly correlated with NF-kappaB activation and disease stage in clinical specimens of ovarian cancer.

203 tumours, with a significant association with disease stage in mucinous EOC subtypes (p = 0.009), lymp

204 flutemetamol retention levels correlate with disease stage in patients with mild cognitive symptoms,

205 We found that disease stage in PD was associated with thinning of the

206 n mouse models of cancer and with increasing disease stage in primary human cancers.

207 onducting quality-controlled trials for this disease stage in the multi-institutional setting.

208 s, Abeta and p-tau were quantified across AD disease stages in parietal cortex.

209 al to the degree of BSCB disruption at early disease stages in SOD1(G93A) mice.

210 uld be a more practical surrogate marker for disease staging in amyotrophic lateral sclerosis (ALS),

211 ve approaches initially developed for binary disease staging in CHC continue to be refined for diagno

212 Pre-HCT disease staging included 10-color multiparametric flow c

213 grade, involvement of lymphovascular space), disease stage (including myometrial invasion), patients'

214 causes of death were progression to advanced disease stage, including complications of stem-cell tran

215 or (AR) is a key transcription factor at all disease stages, including the advanced stage of castrate

216 ing S100B levels are predictive of advancing disease stage, increased recurrence, and low overall sur

217 s (HCV) in 2009, incremental annual costs by disease stage, incremental total Medicare HCV payments i

218 was consistent with or without SEER-Medicare disease stage information (weighted kappa >/= 0.81).

219 The model provides useful disease staging information across the full spectrum of

220 As previously observed, late disease stage-initiated anti-CD20 monotherapy did not in

221 plant included having pretreatment extent of disease stage IV lesions and a longer waiting list time

222 <100 cells/muL or World Health Organization disease stage IV) and determinants of advanced HIV disea

223 the number of chemotherapy cycles received, disease stage, lymph node sampling procedure, performanc

224 that therapeutic interventions at the early disease stage may be effective at alleviating the myopat

225 s, diverse microglial reactions at different disease stages may open new avenues for therapeutic inte

226 a and clinical trials proving the utility of disease-staging modalities and adjuvant therapy is neede

227 of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradi

228 analysis, cardiac involvement, advanced Mayo disease stage, neuropathic involvement, and liver involv

229 ) had stage II, and 439 (30%) had stage IIIA disease (stage of disease data were missing for 43 patie

230 olution of the biomarkers, and (iii) predict disease stages of 57 animals that were naturally infecte

231 en with lifelong ART regardless of CD4 count/disease stage (Option B+) could be the most effective op

232 be attributable to a more advanced glaucoma disease stage or a lower rate of cataract surgery perfor

233 ed with conventional imaging, PET/CT changed disease stage or altered clinical management in 11 (39%)

234 in ALS patients may serve as a biomarker for disease stage or progression.

235 ignificantly larger than differences between disease stages or models.

236 imited either in their representation of the disease stages or use for development of therapeutics du

237 odocytes of patients with DN, independent of disease stage, or BTBR ob/obmice, a model of type 2 diab

238 hysematous and normal voxels with increasing disease stage (P < 0.001).

239 000-2004 vs. 49% in 2005-2009; P<0.001), and disease stage (P = 0.005).

240 ace (P<0.001), insurance type (P=0.005), and disease stage (P<0.001).

241 p<0.0001), and were diagnosed at an earlier disease stage (p=0.006, chi(2) test for trend).

242 e (p=0.029), imaging modality (p=0.019), and disease stage (p=0.025) on sensitivity as well as of pos

243 hyromonas was the most abundant genus in all disease stages, particularly in health along with Moraxe

244 tulate that these lesions define preclinical disease stages, preceding the formation of protein aggre

245 connectivity dynamics significantly improves disease stage prediction.

246 ch remained significant after adjustment for disease stage, prior clinical suspicion, and primary tre

247 ia which may be helpful in the assessment of disease staging, qualification to HSCT and follow-up.

248 Patients at all disease stages report widespread and burdensome multidim

249 alue of MSIS-29 for survival time at earlier disease stages requires further investigation.

250 otor neurons of pathogenic mice at different disease stages revealed elevated expression of markers f

251 oro-parietal hypometabolism, while the later disease stages show overlapping brain atrophy and hypome

252 The syphilis disease stage significantly influences treatment respons

253 Furthermore, disease stage significantly moderated neuroanatomical di

254 ed stratification of the ALS cohort based on disease stage, site of onset, survival and speed of dise

255 ates, all lacking GPL, predominated at later disease stages, some showing variation within rough morp

256 re robust, stable, disease specific, or even disease stage specific.

257 ococcus aureus sepsis, we demonstrate marked disease stage-specific effects of the anticoagulant and

258 IFN-gamma has a disease stage-specific opposing function in EAE.

259 ve cryopreservation, and exhibit ductal- and disease-stage-specific characteristics.

260 s iPSC-based approach can be used to uncover disease-stage-specific responses to drugs.

261 hnologies in oncology might misclassify true disease stage, spuriously informing disease management a

262 zed into the following preclinical Alzheimer disease stages: stage 0 (Abeta-/ND-), stage 1 (Abeta(+)/

263 In later disease stages T2* changes involved deeper cortical lami

264 g action, together with careful selection of disease stage targets and dosing strategies may overcome

265 f the low order Tau oligomers marks an early disease stage that is initiated by Tau phosphorylation a

266 Thus, the patients classified into 6 disease stages, that is, I (n=1494), II (n=8056), III (n

267 Otherwise, at early disease stages, the synaptic physiology phenotype appear

268 o balance, on the basis of comorbidities and disease staging, the potential immediate benefits of tre

269 fferent extents of oligomer formation in the disease stages, thus eliciting early- or adult-onset dia

270 Correlation was made to disease stage, time to recurrence, relapse site, and ove

271 n and ranges from 30% in the early localized disease stage to near 100% in late-stage disease.

272 lution and catalyze its expansion from early disease stage to the myelofibrotic burnt-out phase.

273 .0001) and the difference increased from one disease stage to the next.

274 This reduction ranged from -20% in early disease stages to -61% in late disease stages and preced

275 ion of injured tendons during early and late disease stages to identify disease-specific cleavage pat

276 mplete, pertinent, and accurate reporting of disease staging to optimize treatment recommendations th

277 of M-modules that are important for specific disease stage transitions and offer new insights into th

278 equences to having moderate disease and that disease stage transitions can be anticipated.

279 We also show that disease stage transitions, both reversal and progression

280 The effect of immunotherapy type, disease stage, tumor histology, and concurrent chemother

281 ngle-predictor Cox regression analysis, age, disease stage, tumor weight, somatic TP53 mutations, and

282 ion with a random element stratified by age, disease stage, tumour site, and country.

283 Overall survival, disease staging using international scales, time period

284 motor, executive and behavioural scales and disease staging using the King's college staging system.

285 Disease stage was classified according to the American J

286 Retinal disease staging was done by indirect funduscopy and FAG

287 vity or laryngeal cancers even when standard disease staging was taken into account.

288 For each disease stage, we calculated the number of surgically tr

289 obal Initiative for Chronic Obstructive Lung Disease stage were associated with better treatment resp

290 cerebrovascular disease, and chronic kidney disease stage were independently associated with 6-month

291 Chronic kidney disease stages were classified according to estimated gl

292 gional uptakes for 18F-DTBZ PET of different disease stages were measured.

293 The change of chronic kidney disease stages were recorded and compared with baseline

294 drusen score), pigmentary abnormalities, and disease staging were also evaluated.

295 Fundus features specific for diagnosis and disease staging were retrospectively characterized by sy

296 ls led to tumor eradication even at advanced disease stages where monotherapy with either IL-12 or CT

297 risation and infectiousness of the different disease stages will be crucial to elimination.

298 in dogs, is usually diagnosed at an advanced disease stage with limited response to chemotherapy.

299 HIV disease staging with referral laboratory-based CD4 cell

300 s more generalisable across cancer types and disease stages, with good indices for screening and case